<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155190</url>
  </required_header>
  <id_info>
    <org_study_id>Pelle-926-203</org_study_id>
    <nct_id>NCT04155190</nct_id>
  </id_info>
  <brief_title>An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC</brief_title>
  <official_title>A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients With Non-Gorlin High Frequency BCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PellePharm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PellePharm, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, stratified, vehicle-controlled study of the&#xD;
      efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face&#xD;
      of adult participants with non-Gorlin HF-BCC (high-frequency basal cell carcinoma).&#xD;
      Participants will be randomized (1:1) to receive either Patidegib Topical Gel, 2%, or Vehicle&#xD;
      for 9 months. Randomization will be stratified by gender. The primary endpoint is the number&#xD;
      of nSEB (surgically eligible basal cell carcinoma) that develop on the face over the 9 month&#xD;
      period. The primary end point will be assessed by imaging and tracking of BCCs consistently&#xD;
      throughout the study in order to identify nSEBs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early due to low blinded event rate&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Actual">April 23, 2021</completion_date>
  <primary_completion_date type="Actual">April 23, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized (1:1) to receive either Patidegib Topical Gel, 2%, or Vehicle for 9 months. Randomization will be stratified by gender.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>As a double-blinded study, the Investigators, the site staff, PellePharm, and the Clinical Monitor(s) will be blinded to the treatment assigned to individual subjects. Delegated staff members at the study site will dispense the investigational product (IP) and will collect and weigh all used and unused IP tubes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of new surgically eligible BCCs (nSEBs)</measure>
    <time_frame>Baseline through Month 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events assessed with means and standard errors or proportions</measure>
    <time_frame>Baseline through Month 9</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Recurrent Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patidegib Topical Gel, 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized (1:1) to receive Patidegib Topical Gel, 2% for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patidegib Topical Gel, Vehicle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized (1:1) to receive Patidegib Topical Gel, Vehicle for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patidegib Topical Gel, 2%</intervention_name>
    <description>Patidegib Topical Gel, 2%</description>
    <arm_group_label>Patidegib Topical Gel, 2%</arm_group_label>
    <other_name>IP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patidegib Topical Gel, Vehicle</intervention_name>
    <description>Patidegib Topical Gel, Vehicle</description>
    <arm_group_label>Patidegib Topical Gel, Vehicle</arm_group_label>
    <other_name>IP, Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject must have had at least 10 (with at least 3 on the face) clinically typical&#xD;
             BCCs present within 24 months prior to Screening and Randomization (Baseline/Day 1).&#xD;
             Additionally, the subject must have at least 2 BCCs with longest diameter &lt;5 mm&#xD;
             present on the face prior to Screening and Randomization (Baseline/Day 1).&#xD;
&#xD;
          2. The subject must be willing to abstain from application of a non-study topical&#xD;
             medication (prescription or over the counter) to facial skin for the duration of the&#xD;
             trial except as prescribed by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has been previously diagnosed with Gorlin syndrome&#xD;
&#xD;
          2. On medical history, family history or clinical examination there is a suspicion that&#xD;
             the patient has Gorlin syndrome.&#xD;
&#xD;
          3. Patients with a family history of medulloblastoma&#xD;
&#xD;
          4. The subject has used topical treatment to the face or systemic therapies that might&#xD;
             interfere with the evaluation of the study IP.&#xD;
&#xD;
          5. The subject has uncontrolled systemic disease.&#xD;
&#xD;
          6. The subject has been treated for invasive cancer within the past 5 years excluding&#xD;
             non-melanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the&#xD;
             breast, or chronic lymphocytic leukemia (CLL) Stage 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VP, Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>PellePharm, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Axiom Research, LLC</name>
      <address>
        <city>Apple Valley</city>
        <state>California</state>
        <zip>92307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Research, LLC</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology Center of Newport</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Dermatology Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leavitt Medical Associates of Florida</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PellePharm Investigative Site</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PellePharm Investigative Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Laser and Surgery Specialists of NY&amp;NJ</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Frequency Basal Cell Carcinoma</keyword>
  <keyword>non-gorlin</keyword>
  <keyword>HF-BCC</keyword>
  <keyword>Bazex-Dupré-Christol Syndrome</keyword>
  <keyword>Rombo Syndrome</keyword>
  <keyword>Oley Syndrome</keyword>
  <keyword>Xeroderma Pigmentosum (XP) Syndrome</keyword>
  <keyword>BCC</keyword>
  <keyword>SEB</keyword>
  <keyword>Hedgehog inhibitor</keyword>
  <keyword>Basal Cell Nevus Syndrome</keyword>
  <keyword>Basal Cell Carcinoma</keyword>
  <keyword>Surgically Eligible Basal Cell Carcinoma</keyword>
  <keyword>patidegib</keyword>
  <keyword>HFBCC</keyword>
  <keyword>HHI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Veratrum Alkaloids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

